Comparing Absci (NASDAQ:ABSI) and Opus Genetics (NASDAQ:IRD)

Opus Genetics (NASDAQ:IRD) and Absci (NASDAQ:ABSI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Insider and Institutional Ownership

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 52.0% of Absci shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by company insiders. Comparatively, 10.5% of Absci shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Opus Genetics has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Absci has a beta of 2.42, indicating that its stock price is 142% more volatile than the S&P 500.

Profitability

This table compares Opus Genetics and Absci’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	-338.88%	-150.13%
Absci	-7,756.38%	-61.71%	-54.52%

Valuation and Earnings

This table compares Opus Genetics and Absci”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20 million	27.18	-$49.59 million	($1.35)	-3.46
Absci	$2.80 million	540.57	-$115.18 million	($0.80)	-11.03

Opus Genetics has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Opus Genetics and Absci, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1	1	15	1	2.89
Absci	1	0	8	0	2.78

Opus Genetics currently has a consensus target price of $10.69, suggesting a potential upside of 128.96%. Absci has a consensus target price of $13.43, suggesting a potential upside of 52.25%. Given Opus Genetics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Opus Genetics is more favorable than Absci.

Summary

Opus Genetics beats Absci on 9 of the 15 factors compared between the two stocks.

About Opus Genetics

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

About Absci

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.